RxDoctor Payments Data

Robert Hoffert

Optometrist · Tarpon Springs, FLNPI 1699904946

Payments from drug & device makers

$3,644in general payments, 2019–2025

Across 149 payments — averaging $24.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$692
  • Alcon$605
  • Dompe US, Inc.$380
  • AbbVie$371
  • Bausch & Lomb Americas Inc.$225
  • Astellas Pharma US Inc$223
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,626100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,644 in reported general payments places this provider in the 80th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$223,544
Medicare patients
1,287
Services billed
2,354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine91$122,127
XiidraLifitegrast25$35,120
XdemvyLotilaner15$28,659
Cyclosporine32$19,934
LumiganBimatoprost19$10,122
Lotemax SmLoteprednol Etabonate20$4,989
Tobramycin-DexamethasoneTobramycin/Dexamethasone112$4,673
Latanoprost325$3,825
Alphagan PBrimonidine Tartrate11$2,410
Prednisolone Acetate80$2,153
Brimonidine Tartrate73$1,278
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat85$976
Timolol Maleate103$592
Diclofenac Sodium48$515
Dorzolamide Hcl27$360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$371$134,660121 claims
Bausch & Lomb Americas Inc.Xiidra$225$35,12025 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$122$28,65915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Tarpon Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →